Evaluation of risk in chronic cutaneous inflammatory conditions for malignant transformation
Corresponding Author
Teresa Ju
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Correspondence
Teresa Ju, Dr Phillip Frost Department of Dermatology, University of Miami, Miami, FL, USA.
Email: [email protected]
Search for more papers by this authorLoren Hernandez
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Search for more papers by this authorNoreen Mohsin
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Search for more papers by this authorAngelina Labib
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Search for more papers by this authorFabio Frech
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Search for more papers by this authorKeyvan Nouri
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Search for more papers by this authorCorresponding Author
Teresa Ju
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Correspondence
Teresa Ju, Dr Phillip Frost Department of Dermatology, University of Miami, Miami, FL, USA.
Email: [email protected]
Search for more papers by this authorLoren Hernandez
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Search for more papers by this authorNoreen Mohsin
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Search for more papers by this authorAngelina Labib
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Search for more papers by this authorFabio Frech
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Search for more papers by this authorKeyvan Nouri
Dr Phillip Frost Department of Dermatology, University of Miami, Miami, Florida, USA
Search for more papers by this authorAbstract
Skin carcinomas are the most common form of cancer, and every year thousands of people die from skin cancer-related malignancies. Chronic inflammation is linked to the development and progression of cancer in multiple organ systems – about 20% of all human cancers are a result of chronic inflammation – skin included. While acute inflammation under normal circumstances is a mechanism for host defence and tissue regeneration following insult by trauma or infection by pathogens, over the long term it can drive oncogenic transformation of epithelial cells and promote cancer development, growth and metastasis. Therefore, inflammatory conditions may put individuals at a higher risk to developing skin malignancies. Many skin conditions are characterized by chronic inflammatory processes. These conditions may be particularly susceptible to malignant transformation and predispose patients to develop skin malignancies. As more pathophysiology of chronic inflammatory skin conditions is unveiled, we find that many of these conditions are characterized by immune dysregulation and signalling that result in chronic activation and upregulation of pro-inflammatory chemokines and cytokines, leading to downstream processes that further exacerbate inflammatory processes and cause abnormal cell growth and apoptosis. Here, we review the major chronic cutaneous inflammatory diseases that may have an increased risk of skin malignancies, including atopic dermatitis, psoriasis, discoid lupus erythematosus, lichen planus, hidradenitis suppurativa, prurigo nodularis, lichen sclerosus, systemic sclerosis and morphea, chronic leg ulcers, seborrheic keratoses and basal cell carcinoma. We evaluate the evidence for increased incidence and prevalence, the risk factors associated, the populations at heightened risk and the best management practices.
CONFLICT OF INTEREST
None declared.
Open Research
DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
REFERENCES
- 1Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. PharmacoEconomics. 2011; 29(10): 863–74. https://doi.org/10.2165/11589300-000000000-00000
- 2Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010; 146(3): 283–7. https://doi.org/10.1001/archdermatol.2010.19
- 3Tang L, Wang K. Chronic inflammation in skin malignancies. J Mol Signal. 2016; 11:2. https://doi.org/10.5334/1750-2187-11-2
- 4Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008; 454(7203): 428–35. https://doi.org/10.1038/nature07201
- 5Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013; 13(11): 759–71. https://doi.org/10.1038/nrc3611
- 6Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009; 15(2): 103–13. https://doi.org/10.1016/j.ccr.2009.01.001
- 7Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015; 519(7541): 57–62. https://doi.org/10.1038/nature14228
- 8Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2009; 457(7226): 200–4. https://doi.org/10.1038/nature07475
- 9Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004; 4(2): 97–105. https://doi.org/10.1038/nrc1275
- 10Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010; 49(11): 1603–16. https://doi.org/10.1016/j.freeradbiomed.2010.09.006
- 11Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646–74. https://doi.org/10.1016/j.cell.2011.02.013
- 12Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; 6(5): 392–401. https://doi.org/10.1038/nrc1877
- 13Wang K, Karin M. Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res. 2015; 128: 173–96. https://doi.org/10.1016/bs.acr.2015.04.014
- 14Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 1999; 5(7): 828–31. https://doi.org/10.1038/10552
- 15Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387(10023): 1109–22. https://doi.org/10.1016/s0140-6736(15)00149-x
- 16Vakharia PP, Silverberg JI. Adult-onset atopic dermatitis: characteristics and management. Am J Clin Dermatol. 2019; 20(6): 771–9. https://doi.org/10.1007/s40257-019-00453-7
- 17Hagströmer L, Ye W, Nyrén O, Emtestam L. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol. 2005; 141(9): 1123–7. https://doi.org/10.1001/archderm.141.9.1123
- 18Gandini S, Stanganelli I, Palli D, De Giorgi V, Masala G, Caini S. Atopic dermatitis, naevi count and skin cancer risk: a meta-analysis. J Dermatol Sci. 2016; 84(2): 137–43. https://doi.org/10.1016/j.jdermsci.2016.07.009
- 19Wang L, Bierbrier R, Drucker AM, Chan AW. Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2020; 156(2): 158–71. https://doi.org/10.1001/jamadermatol.2019.3786
- 20Zhu Y, Wang H, He J, Yang L, Zhou X, Li Z, et al. Atopic dermatitis and skin cancer risk: a systematic review. Dermatol Ther (Heidelb). 2022; 12: 1167–79. https://doi.org/10.1007/s13555-022-00720-2
- 21Synnerstad I, Fredrikson M, Ternesten-Bratel A, Rosdahl I. Low risk of melanoma in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2008; 22(12): 1423–8. https://doi.org/10.1111/j.1468-3083.2008.02888.x
- 22Jensen AO, Svaerke C, Körmendiné Farkas D, Olesen AB, Kragballe K, Sørensen HT. Atopic dermatitis and risk of skin cancer: a Danish nationwide cohort study (1977–2006). Am J Clin Dermatol. 2012; 13(1): 29–36. https://doi.org/10.2165/11593280-000000000-00000
- 23Ming ME, Levy R, Hoffstad O, Filip J, Abrams BB, Fernández C, et al. The lack of a relationship between atopic dermatitis and nonmelanoma skin cancers. J Am Acad Dermatol. 2004; 50(3): 357–62. https://doi.org/10.1016/j.jaad.2003.09.024
- 24Cho JM, Davis DMR, Wetter DA, Bartley AC, Brewer JD. Association between atopic dermatitis and squamous cell carcinoma: a case-control study. Int J Dermatol. 2018; 57(3): 313–6. https://doi.org/10.1111/ijd.13857
- 25Maughan WZ, Muller SA, Perry HO, Pittelkow MR, O'Brien PC. Incidence of skin cancers in patients with atopic dermatitis treated with ocal tar. A 25-year follow-up study. J Am Acad Dermatol. 1980; 3(6): 612–5. https://doi.org/10.1016/s0190-9622(80)80075-2
- 26Rodenbeck DL, Silverberg JI, Silverberg NB. Phototherapy for atopic dermatitis. Clin Dermatol. 2016; 34(5): 607–13. https://doi.org/10.1016/j.clindermatol.2016.05.011
- 27Ehrchen J, Sunderkötter C, Luger T, Steinhoff M. Calcineurin inhibitors for the treatment of atopic dermatitis. Expert Opin Pharmacother. 2008; 9(17): 3009–23. https://doi.org/10.1517/14656560802498040
- 28Paller AS, Fölster-Holst R, Chen SC, Diepgen TL, Elmets C, Margolis DJ, et al. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. J Am Acad Dermatol. 2020; 83(2): 375–81. https://doi.org/10.1016/j.jaad.2020.03.075
- 29Thaçi D, Salgo R. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. Clin Dermatol. 2010; 28(1): 52–6. https://doi.org/10.1016/j.clindermatol.2009.04.001
- 30Lam M, Zhu JW, Tadrous M, Drucker AM. Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta-analysis. JAMA Dermatol. 2021; 157(5): 549–58. https://doi.org/10.1001/jamadermatol.2021.0345
- 31Garritsen FM, van der Schaft J, van den Reek JM, Politiek K, van Os-Medendorp H, van Dijk M, et al. Risk of non-melanoma skin cancer in patients with atopic dermatitis treated with Oral immunosuppressive drugs. Acta Derm Venereol. 2017; 97(6): 724–30. https://doi.org/10.2340/00015555-2637
- 32Greif CS, Srivastava D, Nijhawan RI. Janus kinase inhibitors and non-melanoma skin cancer. Curr Treat Options in Oncol. 2021; 22(2):11. https://doi.org/10.1007/s11864-020-00815-y
- 33Twelves S, Mostafa A, Dand N, Burri E, Farkas K, Wilson R, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019; 143(3): 1021–6. https://doi.org/10.1016/j.jaci.2018.06.038
- 34Amin M, Lee EB, Tsai TF, Wu JJ. Psoriasis and Co-morbidity. Acta Derm Venereol. 2020; 100(3):adv00033. https://doi.org/10.2340/00015555-3387
- 35Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020; 156(4): 421–9. https://doi.org/10.1001/jamadermatol.2020.0024
- 36Boffetta P, Gridley G, Lindelöf B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol. 2001; 117(6): 1531–7. https://doi.org/10.1046/j.0022-202x.2001.01520.x
- 37Brauchli YB, Jick SS, Miret M, Meier CR. Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol. 2009; 129(11): 2604–12. https://doi.org/10.1038/jid.2009.113
- 38Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol. 1988; 91(3): 197–201. https://doi.org/10.1111/1523-1747.ep12464847
- 39Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol. 2010; 163(3): 586–92. https://doi.org/10.1111/j.1365-2133.2010.09941.x
- 40Wang X, Liu Q, Wu L, Nie Z, Mei Z. Risk of non-melanoma skin cancer in patients with psoriasis: an updated evidence from systematic review with meta-analysis. J Cancer. 2020; 11(5): 1047–55. https://doi.org/10.7150/jca.37015
- 41Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013; 27(Suppl 3): 36–46. https://doi.org/10.1111/jdv.12165
- 42Peleva E, Exton LS, Kelley K, Kleyn CE, Mason KJ, Smith CH. Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol. 2018; 178(1): 103–13. https://doi.org/10.1111/bjd.15830
- 43Egeberg A, Thyssen JP, Gislason GH, Skov L. Skin cancer in patients with psoriasis. J Eur Acad Dermatol Venereol. 2016; 30(8): 1349–53. https://doi.org/10.1111/jdv.13619
- 44Reddy SP, Martires K, Wu JJ. The risk of melanoma and hematologic cancers in patients with psoriasis. J Am Acad Dermatol. 2017; 76(4): 639–647.e2. https://doi.org/10.1016/j.jaad.2016.09.047
- 45Trafford AM, Parisi R, Kontopantelis E, Griffiths CEM, Ashcroft DM. Association of Psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis. JAMA Dermatol. 2019; 155(12): 1390–403. https://doi.org/10.1001/jamadermatol.2019.3056
- 46Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clin Dermatol. 2010; 28(1): 88–92. https://doi.org/10.1016/j.clindermatol.2009.03.003
- 47Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917): 860–7. https://doi.org/10.1038/nature01322
- 48Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013; 27(3): 391–404. https://doi.org/10.1016/j.berh.2013.07.008
- 49Tao J, Zhang X, Guo N, Chen S, Huang C, Zheng L, et al. Squamous cell carcinoma complicating discoid lupus erythematosus in Chinese patients: review of the literature, 1964-2010. J Am Acad Dermatol. 2012; 66(4): 695–6. https://doi.org/10.1016/j.jaad.2011.09.033
- 50Millard LG, Barker DJ. Development of squamous cell carcinoma in chronic discoid lupus erythematosus. Clin Exp Dermatol. 1978; 3(2): 161–6. https://doi.org/10.1111/j.1365-2230.1978.tb01480.x
- 51Dieng MT, Diop NN, Déme A, Sy TN, Niang SO, Ndiaye B. Squamous cell carcinoma in black patients: 80 cases. Ann Dermatol Venereol. 2004; 131(12): 1055–7. Carcinome épidermoïde sur peau noire: 80 cas. https://doi.org/10.1016/s0151-9638(04)93840-9
- 52Ma D, Dai G, Guo C. Carcinoma of the lips developing in discoid lupus erythematosus. Zhonghua Kou Qiang Yi Xue Za Zhi. 1999; 34(1): 13–5.
- 53Liu W, Shen ZY, Wang LJ, Hu YH, Shen XM, Zhou ZT, et al. Malignant potential of oral and labial chronic discoid lupus erythematosus: a clinicopathological study of 87 cases. Histopathology. 2011; 59(2): 292–8. https://doi.org/10.1111/j.1365-2559.2011.03934.x
- 54Grönhagen CM, Fored CM, Granath F, Nyberg F. Increased risk of cancer among 3663 patients with cutaneous lupus erythematosus: a Swedish nationwide cohort study. Br J Dermatol. 2012; 166(5): 1053–9. https://doi.org/10.1111/j.1365-2133.2011.10773.x
- 55Simpson JK, Medina-Flores R, Deng JS. Squamous cell carcinoma arising in discoid lupus erythematosus lesions of the ears infected with human papillomavirus. Cutis. 2010; 86(4): 195–8.
- 56Zaalberg A, Moradi Tuchayi S, Ameri AH, Ngo KH, Cunningham TJ, Eliane JP, et al. Chronic inflammation promotes skin carcinogenesis in cancer-prone discoid lupus erythematosus. J Invest Dermatol. 2019; 139(1): 62–70. https://doi.org/10.1016/j.jid.2018.06.185
- 57Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000; 42(6): 983–7.
- 58Le Cleach L, Chosidow O. Lichen Planus. N Engl J Med. 2012; 366(8): 723–32. https://doi.org/10.1056/nejmcp1103641
- 59Wagner G, Rose C, Sachse MM. Clinical variants of lichen planus. JDDG: J Dtsch Dermatol Ges. 2013; 11(4): 309–19. https://doi.org/10.1111/ddg.12031
- 60Lavanya N, Jayanthi P Fau - Rao UK, Rao Uk Fau - Ranganathan K, Ranganathan K. Oral lichen planus: An update on pathogenesis and treatment. (1998-393X [Electronic]).
- 61Sigurgeirsson B. Lichen planus and malignancy. Arch Dermatol. 1991; 127(11):1684. https://doi.org/10.1001/archderm.1991.01680100084009
- 62Halonen P, Jakobsson M, Heikinheimo O, Riska A, Gissler M, Pukkala E. Cancer risk of Lichen planus: a cohort study of 13,100 women in Finland. Int J Cancer. 2018; 142(1): 18–22. doi:10.1002/ijc.31025
- 64Manz B, Paasch U, Sticherling M. Squamous cell carcinoma as a complication of long-standing hypertrophic lichen planus. Int J Dermatol. 2005; 44(9): 773–4. https://doi.org/10.1111/j.1365-4632.2004.02202.x
- 65Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002; 46(2): 207–14. https://doi.org/10.1067/mjd.2002.120452
- 66Franck JM, Young AW Jr. Squamous cell carcinoma in situ arising within lichen planus of the vulva. Dermatol Surg. 1995; 21(10): 890–4.
- 67Lewis FM, Harrington CI. Squamous cell carcinoma arising in vulval lichen planus. Br J Dermatol. 1994; 131(5): 703–5. https://doi.org/10.1111/j.1365-2133.1994.tb04987.x
- 68Dwyer CM, Kerr REI, Millan DWM. Squamous carcinoma following lichen planus of the vulva. Clin Exp Dermatol. 1995; 20(2): 171–2. https://doi.org/10.1111/j.1365-2230.1995.tb02677.x
- 69Regauer S, Reich O, Eberz B. Vulvar cancers in women with vulvar lichen planus: a clinicopathological study. J Am Acad Dermatol. 2014; 71(4): 698–707. https://doi.org/10.1016/j.jaad.2014.05.057
- 70Cooper SM, Wojnarowska F. Influence of treatment of erosive lichen planus of the vulva on its prognosis. Arch Dermatol. 2006; 142(3). doi:10.1001/archderm.142.3.289
10.1001/archderm.142.3.289 Google Scholar
- 71Lo Muzio L, Mignogna MD, Favia G, Procaccini M, Testa NF, Bucci E. The possible association between oral lichen planus and oral squamous cell carcinoma: a clinical evaluation on 14 cases and a review of the literature. Oral Oncol. 1998; 34(4): 239–46. https://doi.org/10.1016/S1368-8375(98)80001-8
- 72Murti PR, Daftary DK, Bhonsle RB, Gupta PC, Mehta FS, Pindborg JJ. Malignant potential of oral lichen planus: observations in 722 patients from India. J Oral Pathol Med. 1986; 15(2): 71–7. https://doi.org/10.1111/j.1600-0714.1986.tb00580.x
- 73Silverman S, Gorsky M, Lozada-Nur F, Giannotti K. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol. 1991; 72(6): 665–70. https://doi.org/10.1016/0030-4220(91)90007-y
- 74Markopoulos A, Antoniades D, Papanayotou P, Trigonidis G. Malignant potential of oral lichen planus: a follow-up study of 326 patients. Oral Oncol. 1997; 33(4): 263–9. https://doi.org/10.1016/s0964-1955(97)00005-5
- 75Voute ABE, Jong WFB, Schulten EAJM, Snow GB, Waal I. Possible premalignant character of oral lichen planus the Amsterdam experience. J Oral Pathol Med. 1992; 21(7): 326–9. https://doi.org/10.1111/j.1600-0714.1992.tb01020.x
- 76Gandolfo S, Richiardi L, Carrozzo M, Broccoletti R, Carbone M, Pagano M, et al. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population. Oral Oncol. 2004; 40(1): 77–83. https://doi.org/10.1016/S1368-8375(03)00139-8
- 77Gonzalez-Moles MA, Scully C, Gil-Montoya JA. Oral lichen planus: controversies surrounding malignant transformation. Oral Dis. 2008; 14(3): 229–43. https://doi.org/10.1111/j.1601-0825.2008.01441.x
- 78Asarch A, Gottlieb AB, Lee J, Masterpol KS, Scheinman PL, Stadecker MJ, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol. 2009; 61(1): 104–11. https://doi.org/10.1016/j.jaad.2008.09.032
- 79Pagkopoulou E, Arvanitaki A, Daoussis D, Garyfallos A, Kitas G, Dimitroulas T. Comorbidity burden in systemic sclerosis: beyond disease-specific complications. Rheumatol Int. 2019; 39(9): 1507–17. https://doi.org/10.1007/s00296-019-04371-z
- 80Igusa T, Hummers LK, Visvanathan K, Richardson C, Wigley FM, Casciola-Rosen L, et al. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis. 2018; 77(8): 1179–86. https://doi.org/10.1136/annrheumdis-2018-212999
- 81Zeineddine N, Khoury LE, Mosak J. Systemic sclerosis and malignancy: a review of current data. J Clin Med Res. 2016; 8(9): 625–32. https://doi.org/10.14740/jocmr2606w
- 82Grewal I, Khan O, Davis W. Squamous cell carcinoma and eosinophilia in a long-term course of pansclerotic morphea. BMJ Case Rep. 2014; 2014:bcr2014205737. https://doi.org/10.1136/bcr-2014-205737
- 83Boozalis E, Shah AA, Wigley F, Kang S, Kwatra SG. Morphea and systemic sclerosis are associated with an increased risk for melanoma and nonmelanoma skin cancer. J Am Acad Dermatol. 2019; 80(5): 1449–51. https://doi.org/10.1016/j.jaad.2018.10.022
- 84Travis LB, Curtis RE, Glimelius B, Holowaty EJ, van Leeuwen F, Lynch CF, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1995; 87(7): 524–30. https://doi.org/10.1093/jnci/87.7.524
- 85Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996; 124(5): 477–84. https://doi.org/10.7326/0003-4819-124-5-199603010-00003
- 86Barbosa NS, Wetter DA, Wieland CN, Shenoy NK, Markovic SN, Thanarajasingam U. Scleroderma induced by pembrolizumab: a case series. Mayo Clin Proc. 2017; 92(7): 1158–63. https://doi.org/10.1016/j.mayocp.2017.03.016
- 87Silva JL, Faria DS, Teixeira F, Afonso MC, Peixoto D. Systemic sclerosis induced by interferon-alfa treatment of melanoma. Acta Reumatol Port. 2017; 42(3): 263–4.
- 88Cho M, Nonomura Y, Kaku Y, Nakabo S, Endo Y, Otsuka A, et al. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma. J Dermatol. 2019; 46(1): e43–4. https://doi.org/10.1111/1346-8138.14492
- 89Jemec GB. Hidradenitis suppurativa. N Engl J Med. 2012; 366(2): 158–64.
- 90Kohorst JJ, Kimball AB, Davis MDP. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015; 73(5 Suppl 1): S27–35. https://doi.org/10.1016/j.jaad.2015.07.055
- 91Lapins J, Ye W, Nyrén O, Emtestam L. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol. 2001; 137(6): 730–4.
- 92Lavogiez C, Delaporte E, Darras-Vercambre S, Martin de Lassalle E, Castillo C, Mirabel X, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology. 2010; 220(2): 147–53.
- 93Crisafulli S, Bertino L, Fontana A, Calapai F, Ingrasciotta Y, Berretta M, et al. Incidence of skin cancer in patients with chronic inflammatory cutaneous diseases on targeted therapies: a systematic review and meta-analysis of observational studies. Front Oncol. 2021; 11: 2058.
- 94Jung JM, Lee KH, Kim Y-J, Chang SE, Lee MW, Choi JH, et al. Assessment of overall and specific cancer risks in patients with hidradenitis suppurativa. JAMA Dermatol. 2020; 156(8): 844–53. https://doi.org/10.1001/jamadermatol.2020.1422
- 95Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysis. J Am Acad Dermatol. 2014; 71(6): 1144–50. https://doi.org/10.1016/j.jaad.2014.09.012
- 96Chapman S, Delgadillo D, Barber C, Khachemoune A. Cutaneous squamous cell carcinoma complicating hidradenitis suppurativa: a review of the prevalence, pathogenesis, and treatment of this dreaded complication. Acta Dermatovenerol Alp Pannonica Adriat. 2018; 27(1): 25–8.
- 97Li Pomi F, Macca L, Motolese A, Ingrasciotta Y, Berretta M, Guarneri C. Neoplastic implications in patients suffering from hidradenitis suppurativa under systemic treatments. Biomedicine. 2021; 9(11): 1594.
- 98Kelly G, Sweeney CM, Tobin AM, Kirby B. Hidradenitis suppurativa: the role of immune dysregulation. Int J Dermatol. 2014; 53(10): 1186–96. https://doi.org/10.1111/ijd.12550
- 99Fistarol SK, Itin PH. Diagnosis and treatment of lichen Sclerosus. Am J Clin Dermatol. 2013; 14(1): 27–47. https://doi.org/10.1007/s40257-012-0006-4
- 100Henquet C. Anogenital malignancies and pre-malignancies. J Eur Acad Dermatol Venereol. 2011; 25(8): 885–95.
- 101Gutiérrez-Pascual M, Vicente-Martín FJ, López-Estebaranz JL. Lichen Sclerosus and squamous cell carcinoma. Actas Dermo-Sifiliográficas (English Edition). 2012; 103(1): 21–8. https://doi.org/10.1016/j.adengl.2011.05.004
10.1016/j.adengl.2011.05.004 Google Scholar
- 102Walkden V, Chia Y, Wojnarowska F. The association of squamous cell carcinoma of the vulva and lichen sclerosus: implications for management and follow up. J Obstet Gynaecol. 1997; 17(6): 551–3. https://doi.org/10.1080/01443619768588
- 103Hart WR, Norris HJ, Helwig EB. Relation of lichen sclerosus et atrophicus of the vulva to development of carcinoma. Obstet Gynecol. 1975; 45(4): 369–77.
- 104Nasca MR, Innocenzi D, Micali G. Penile cancer among patients with genital lichen sclerosus. J Am Acad Dermatol. 1999; 41(6): 911–4. https://doi.org/10.1016/s0190-9622(99)70245-8
- 105Poulsen H, Junge J, Vyberg M, Horn T, Lundvall F. Small vulvar squamous cell carcinomas and adjacent tissues. A morphologic study. APMIS. 2003; 111(9): 835–42. https://doi.org/10.1034/j.1600-0463.2003.1110901.x
- 106Powell J, Robson A, Cranston D, Wojnarowska F, Turner R. High incidence of lichen sclerosus in patients with squamous cell carcinoma of the penis. Br J Dermatol. 2001; 145(1): 85–9. https://doi.org/10.1046/j.1365-2133.2001.04287.x
- 107Leibowttch M, Neill S, Pelisse M, Moyal-Baracco M. The epithelial changes associated with squamous cell carcinoma of the vulva: a review of the clinical, histological and viral findings in 78 women. BJOG. 1990; 97(12): 1135–9. https://doi.org/10.1111/j.1471-0528.1990.tb02502.x
- 108Rolfe K, MacLean A, Crow J, Benjamin E, Reid W, Perrett C. TP53 mutations in vulval lichen sclerosus adjacent to squamous cell carcinoma of the vulva. Br J Cancer. 2003; 89(12): 2249–53.
- 109Guerrero D, Guarch R, Ojer A, Casas JM, Méndez-Meca C, Esteller M, et al. Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer. Int J Cancer. 2011; 128(12): 2853–64.
- 110Zeidler C, Yosipovitch G, Ständer S. Prurigo Nodularis and its management. Dermatol Clin. 2018; 36(3): 189–97. https://doi.org/10.1016/j.det.2018.02.003
- 111Williams KA, Roh YS, Brown I, Sutaria N, Bakhshi P, Choi J, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021; 14(1): 67–77. https://doi.org/10.1080/17512433.2021.1852080
- 112Mullins TB, Sharma P, Riley CA, Sonthalia S. Prurigo Nodularis. StatPearls. Treasure Island, FL: StatPearls Publishing; 2022.
- 114Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Ständer S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol. 2013; 27(5): 550–7. https://doi.org/10.1111/j.1468-3083.2012.04481.x
- 115Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020; 83(6): 1559–65. https://doi.org/10.1016/j.jaad.2020.04.183
- 116Larson VA, Tang O, Stander S, Miller LS, Kang S, Kwatra SG. Association between prurigo nodularis and malignancy in middle-aged adults. J Am Acad Dermatol. 2019; 81(5): 1198–201. https://doi.org/10.1016/j.jaad.2019.03.083
- 117Jedlowski PM, Fazel M, Foshee JP, Curiel-Lewandrowski C. A patient with concurrent prurigo nodularis and squamous cell carcinomas of keratoacanthoma type: the role of aprepitant in diagnostic clarity. JAAD Case Rep. 2020; 6(1): 3–5. https://doi.org/10.1016/j.jdcr.2019.10.014
- 118Al-Waiz MM, Maluki AH. Squamous cell carcinoma complicating prurigo nodularis. Saudi Med J. 2000; 21(3): 300–1.
- 119Trent JT, Kirsner RS. Wounds and malignancy. Adv Skin Wound Care. 2003; 16(1): 31–4. https://doi.org/10.1097/00129334-200301000-00014
- 120Bazaliński D, Przybek-Mita J, Barańska B, Więch P. Marjolin's ulcer in chronic wounds - review of available literature. Contemp Oncol (Pozn). 2017; 21(3): 197–202. https://doi.org/10.5114/wo.2017.70109
- 121Senet P, Combemale P, Debure C, Baudot N, Machet L, Aout M, et al. Malignancy and chronic leg ulcers: the value of systematic wound biopsies: a prospective, multicenter, cross-sectional study. Arch Dermatol. 2012; 148(6): 704–8. https://doi.org/10.1001/archdermatol.2011.3362
- 122Miller D, Enoch S, Williams DT, Price PE, Harding KG. Value of wound biopsy in chronic venous ulceration. Phlebology. 2004; 19(2): 65–8.
- 123Baldursson B, Sigurgeirsson B, Lindelöf B. Venous leg ulcers and squamous cell carcinoma: a large-scale epidemiological study. Br J Dermatol. 1995; 133(4): 571–4. https://doi.org/10.1111/j.1365-2133.1995.tb02707.x
- 124Combemale P, Bousquet M, Kanitakis J, Bernard P. Malignant transformation of leg ulcers: a retrospective study of 85 cases. J Eur Acad Dermatol Venereol. 2007; 21(7): 935–41. https://doi.org/10.1111/j.1468-3083.2006.02118.x
- 125Turk BG, Bozkurt A, Yaman B, Ozdemir F, Unal I. Melanoma arising in chronic ulceration associated with lymphoedema. J Wound Care. 2013; 22(2): 74–5. https://doi.org/10.12968/jowc.2013.22.2.74
- 126Karadag AS, Parish LC. The status of the seborrheic keratosis. Clin Dermatol. 2018; 36(2): 275–7. https://doi.org/10.1016/j.clindermatol.2017.09.011
- 127Vun Y, De'Ambrosis B, Spelman L, Muir JB, Yong-Gee S, Wagner G, et al. Seborrhoeic keratosis and malignancy: collision tumour or malignant transformation? Australas J Dermatol. 2006; 47(2): 106–8. https://doi.org/10.1111/j.1440-0960.2006.00242.x
- 128Cascajo CD, Reichel M, Sánchez JL. Malignant neoplasms associated with seborrheic keratoses. An analysis of 54 cases. Am J Dermatopathol. 1996; 18(3): 278–82. https://doi.org/10.1097/00000372-199606000-00007
- 129Lim C. Seborrhoeic keratoses with associated lesions: a retrospective analysis of 85 lesions. Australas J Dermatol. 2006; 47(2): 109–13. https://doi.org/10.1111/j.1440-0960.2006.00258.x
- 130Mikhail GR, Mehregan AH. Basal cell carcinoma in seborrheic keratosis. J Am Acad Dermatol. 1982; 6(4 Pt 1): 500–6. https://doi.org/10.1016/s0190-9622(82)70042-8
- 131Gaffney DC, Muir JB, De'Ambrosis B. Malignant change in seborrhoeic keratoses in a region with high solar ultraviolet levels. Australas J Dermatol. 2014; 55(2): 142–4. https://doi.org/10.1111/ajd.12035
- 132Izikson L, Sober AJ, Mihm MC Jr, Zembowicz A. Prevalence of melanoma clinically resembling seborrheic keratosis: analysis of 9204 cases. Arch Dermatol. 2002; 138(12): 1562–6. https://doi.org/10.1001/archderm.138.12.1562
- 133Dinehart M, Abate MS, Jennings T, Kaley JR, Shalin SC. Colliding, colonizing or combining? Four cases illustrating the unique challenges presented by melanoma arising in conjunction with basal cell carcinoma. J Cutan Pathol. 2018; 45(6): 443–52. https://doi.org/10.1111/cup.13137
- 134Mancebo SE, Marchetti MA, Hollmann TJ, Marghoob AA, Busam KJ, Halpern AC. Melanoma in situ colonizing basal cell carcinoma: a case report and review of the literature. Dermatol Pract Concept. 2015; 5(1): 25–30. https://doi.org/10.5826/dpc.0501a04
- 135Amin SM, Cooper C, Yélamos O, Lee CY, Sholl LM, de la Fouchardiere A, et al. Combined cutaneous tumors with a melanoma component: a clinical, histologic, and molecular study. J Am Acad Dermatol. 2015; 73(3): 451–60. https://doi.org/10.1016/j.jaad.2015.06.005
- 136Lai KKH, Chan E, Ko SC. Combination of squamous cell carcinoma and basal cell carcinoma arising from a giant verruca vulgaris involving the eyelid. Am J Ophthalmol Case Rep. 2021; 21:100858. https://doi.org/10.1016/j.ajoc.2020.100858